Poplar Point trims NovaBay stake to 0.81%
Poplar Point Capital Management LLC and related reporting persons report beneficial ownership of 1,020,300 shares of NovaBay Pharmaceuticals common stock, representing 0.81% of the outstanding shares.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Poplar Point Capital Management LLC and related reporting persons report beneficial ownership of 1,020,300 shares of NovaBay Pharmaceuticals common stock, representing 0.81% of the outstanding shares. The filing notes that NovaBay issued additional shares after a vote of security holders, which reduced the group’s stake below the 5% Schedule 13D reporting threshold.
The shares are held through Poplar Point Capital Management, Poplar Point Capital Partners, Poplar Point Capital GP and Jad Fakhry, who share voting and dispositive power over the position. The reporting persons state there have been no recent acquisitions or dispositions, but as of the effective date they intend to begin disposing of their NovaBay common stock.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake in NovaBay Pharmaceuticals (NBY) does Poplar Point report in this Schedule 13D/A?
Why did Poplar Point file Amendment No. 3 to its Schedule 13D on NovaBay (NBY)?
Who are the reporting persons in the NovaBay (NBY) Schedule 13D/A amendment?
Did Poplar Point report any recent NovaBay (NBY) trades in the 60 days before this filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.